Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B.
Siegall, Ph.D., President and Chief Executive Officer, will present at
the 32nd Annual J.P. Morgan Healthcare Conference on Monday,
January 13, 2014 at 9:30 a.m. Pacific Time. The presentation will be
webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com
in the Investors
and News section.
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development
and commercialization of innovative antibody-based therapies for the
treatment of cancer. Seattle Genetics is leading the field in developing
antibody-drug conjugates (ADCs), a technology designed to harness the
targeting ability of antibodies to deliver cell-killing agents directly
to cancer cells. The company’s lead product, ADCETRIS®
(brentuximab vedotin) is an ADC that, in collaboration with Takeda
Pharmaceutical Company Limited, has been approved for two indications in
more than 35 countries, including the U.S., Canada and members of the
European Union. Additionally, ADCETRIS is being evaluated broadly in
more than 20 ongoing clinical trials. Seattle Genetics is also advancing
a robust pipeline of clinical-stage ADC programs, including SGN-CD19A,
SGN-CD33A, SGN-LIV1A, ASG-22ME and ASG-15ME. Seattle Genetics has
collaborations for its ADC technology with a number of leading
biotechnology and pharmaceutical companies, including AbbVie, Agensys
(an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and
Pfizer. More information can be found at www.seattlegenetics.com.
Copyright Business Wire 2014